Citizens Jmp Issues Positive Forecast for Pharvaris (NASDAQ:PHVS) Stock Price

Pharvaris (NASDAQ:PHVS) had its target price lifted by investment analysts at Citizens Jmp from $75.00 to $79.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price target suggests a potential upside of 108.77% from the stock’s previous close.

A number of other brokerages also recently issued reports on PHVS. HSBC raised Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Wedbush restated an “outperform” rating and issued a $42.00 price target on shares of Pharvaris in a research note on Tuesday. UBS Group set a $79.00 price target on shares of Pharvaris in a report on Wednesday. Oppenheimer reiterated an “outperform” rating and issued a $75.00 price objective on shares of Pharvaris in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.46.

Pharvaris Stock Up 7.3%

Pharvaris stock opened at $37.84 on Wednesday. Pharvaris has a twelve month low of $20.65 and a twelve month high of $43.25. The business has a fifty day moving average of $34.86 and a two-hundred day moving average of $31.20. The firm has a market cap of $2.48 billion, a P/E ratio of -12.41 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities analysts expect that Pharvaris will post -3.15 earnings per share for the current year.

Insider Buying and Selling at Pharvaris

In other Pharvaris news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the sale, the director owned 315,167 shares in the company, valued at $11,185,276.83. This represents a 8.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Anne Lesage sold 30,703 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47. Following the transaction, the insider directly owned 93,969 shares of the company’s stock, valued at $3,334,959.81. This trade represents a 24.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 118,655 shares of company stock worth $4,188,002 in the last ninety days. 11.84% of the stock is owned by insiders.

Institutional Trading of Pharvaris

Hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP bought a new position in shares of Pharvaris during the 2nd quarter valued at $1,143,000. Amundi increased its position in Pharvaris by 61.4% during the second quarter. Amundi now owns 49,944 shares of the company’s stock worth $1,727,000 after acquiring an additional 18,992 shares during the period. California State Teachers Retirement System raised its position in shares of Pharvaris by 3,210.1% during the second quarter. California State Teachers Retirement System now owns 799,490 shares of the company’s stock valued at $27,646,000 after buying an additional 775,337 shares during the last quarter. Moore Capital Management LP bought a new stake in shares of Pharvaris in the 2nd quarter worth approximately $1,522,000. Finally, Alyeska Investment Group L.P. increased its holdings in Pharvaris by 225.5% in the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock valued at $14,068,000 after buying an additional 281,829 shares during the period.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Positive Phase 3 CHAPTER-3 results: Deucrictibant XR met the primary endpoint and all secondary efficacy endpoints with statistical significance in the pivotal study, demonstrating a reduction in HAE attacks. Pharvaris plans to use the results to support marketing-authorization applications beginning in the first half of 2027. Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study
• Positive Sentiment: Late-stage drug validation: Reports characterized the experimental oral therapy as meeting the main goal of the trial, a potentially important advantage in HAE, where patients may value an oral preventive option. The results helped drive the stock higher and strengthened expectations for Pharvaris’ pipeline. Pharvaris’ genetic disorder drug meets main goal in late-stage trial
• Positive Sentiment: Analyst support increased: HC Wainwright reaffirmed a “buy” rating and set a $60 price target, while Wedbush maintained an “outperform” rating with a $42 target. A separate report placed the analyst consensus target at $51.08, indicating continued upside expectations if the program advances successfully. Analysts Set Pharvaris Price Target at $51.08
• Neutral Sentiment: The topline results are encouraging but additional regulatory review, application submissions, and potential approval remain ahead. Pharvaris is also a loss-making clinical-stage company, so valuation will remain sensitive to development, regulatory, and commercialization risks.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.